시장보고서

상품코드

1587400

병리 검사실 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 검사 서비스별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Pathology Laboratories Market Size, Share & Trends Analysis Report By Type, By Testing Services, By End-use, By Region, And Segment Forecasts, 2025 - 2030

발행일: 2024년 10월 | 리서치사:

Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

병리 검사실 시장 성장과 동향:

Grand View Research, Inc.의 최신 보고서에 따르면 세계 병리 실험실 시장 규모는 2025년부터 2030년까지 연평균 8.1%의 CAGR을 기록하여 2030년에는 6,122억 2,000만 달러에 달할 것으로 예상됩니다.

산업 성장의 주요 요인으로는 평균 수명 증가, 개발도상국의 의료 인프라 구축, 의료비 상환 촉진, 정기 검진 수요 증가 등을 꼽을 수 있습니다.

또한, 기술의 발전은 진단의 역학 관계를 변화시키고 있습니다. 혁신적인 기술로 인해 POCT(Point of Care Testing) 기기의 휴대성이 향상되고 샘플링 기술이 개선되어 진단 서비스가 더욱 친숙하고 효율성이 높아졌습니다. 몇 가지 발전은 품질, 속도, 효율성, 확장성을 통해 환자 치료의 방향을 잡고 업계를 변화시킬 것으로 예상됩니다. 의료 시스템은 병리 및 진단 실험실의 중요성을 점차 강조하고 있으며, 병리 및 진단 실험실이 환자를 더 빠르고 정확하게 모니터링할 뿐만 아니라 의사의 추론과 진단을 돕고 더 큰 임상 의사결정 엔진이 될 수 있도록 지원하고 있습니다.

COVID-19 팬데믹으로 인해 COVID-19 검사에 대한 수요가 증가하면서 병리 및 진단 검사실에 대한 수요가 증가했으며, COVID-19 감염이 급증하면서 자금과 검사가 증가하여 전체 시장 성장을 촉진했습니다. 예를 들어, 미국 국립보건원(NIH)은 2020년 9월 미국 내 COVID-19 진단을 강화하기 위한 이니셔티브의 일환으로 Maxim Biomedical Inc. International 등 9개 단체에 1억 2,930만 달러의 자금을 지원한다고 발표했습니다.

병리 검사실 시장 보고서 하이라이트

유형별로는 병원 기반 진단 연구소가 2024년 시장을 장악했습니다. 이는 병원에서 사용할 수 있는 고급 검사가 복잡한 진단을 위한 유일한 최상의 솔루션이 되었기 때문입니다.
최종 용도를 기준으로 2024년에는 의사 의뢰가 시장을 주도했습니다. 워크 인 및 기업 고객은 개인 건강 및 웰빙 모니터링에 대한 인식이 높아짐에 따라 유리한 성장을 보일 것으로 예상됩니다.
미국은 미국에서 가장 두드러진 질병으로 인해 심혈관 건강 진단에 대한 수요가 높을 것으로 예상됩니다.
유럽은 예측 기간 동안 큰 CAGR을 보일 것으로 예상됩니다. 세계 암 연구 기금에 따르면 덴마크는 전 세계적으로 암 유병률이 가장 높은 국가입니다.
최근 이 시장에서는 주요 기업들이 서비스 부가가치 향상과 연구 확대를 위해 여러 공동연구를 진행하고 있습니다. 예를 들어, 2022년 7월 유니랩은 Subtle Medical과 파트너십을 체결하고 고품질의 신속한 MRI를 위해 AI 기반 MRI 기술을 채택한 최초의 진단 기업이 될 것이라고 발표했습니다. 이 솔루션은 스웨덴에서 먼저 출시될 예정입니다.

부문 대시보드
병리 검사실 시장 : 검사 서비스 변동 분석
병리 검사실 시장 : 검사 서비스별 전망
2018년부터 2030년까지 시장 규모와 예측 및 동향 분석
일반적인 생리학적 검사 및 임상 검사
영상 검사 및 방사선 검사
난해한 검사
COVID-19 검사

제6장 병리 검사실 시장 : 최종 용도 추정·동향 분석

부문 대시보드
병리 검사실 시장 : 최종 용도 변동 분석
병리 검사실 시장 : 최종 용도별 전망
2018년부터 2030년까지 시장 규모와 예측 및 동향 분석
의사 소개
워크인
기업

제7장 병리 검사실 시장 : 지역 추정·동향 분석

지역별 대시보드
시장 규모, 예측 동향 분석, 2018년에서 2030년
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 노르웨이
- 스웨덴
- 덴마크
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트

제8장 경쟁 상황

시장 진출 기업 분류
주요 시장 진출 기업의 최근 동향과 영향 분석
기업 시장 점유율 분석, 2024년
주요 기업 개요
- Quest Diagnostics Incorporated
- Eurofins Scientific
- Laboratory Corporation of America Holdings
- Exact Sciences Laboratories LLC
- Spectra Laboratories
- SYNLAB International GmbH
- Sonic Healthcare Limited
- DR Lal Path Labs.
- Metropolis Healthcare
- Kingmed Diagnostics

ksm 24.11.20

Pathology Laboratories Market Growth & Trends:

The global pathology laboratories market size is estimated to reach USD 612.22 billion by 2030, registering a CAGR of 8.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The major factors driving the industry include increasing life expectancy, the development of healthcare infrastructure in developing nations, favoring reimbursement, and rising demand for routine medical check-ups.

In addition, the advancement of technology is altering the dynamics of diagnosis. Innovative technologies have made Point of Care Testing(POCT) devices portable and improved sampling techniques, making diagnostic services more accessible and efficient. Several advancements are expected to transform the industry by steering patient care through quality, speed, efficiency, and scalability. The healthcare system is progressively emphasizing the importance of pathological & diagnostic labs in becoming a greater clinical decision-making engine, assisting physicians in making inferences and diagnosing as well as monitoring patients more quickly and accurately.

The COVID-19 pandemic has resulted in higher demand for pathology/diagnostic labs as the testing for COVID-19 was necessary during the pandemic. The rapid rise of COVID-19 infections has resulted in increased funding and testing, which has boosted the overall market growth. For instance, the (NIH) National Institutes of Health in the United States announced in September 2020 that it would grant USD 129.3 million in funding to nine organizations including, Maxim Biomedical Inc., MatMaCorp, MicroGEM International, & others, for scaling-up manufacturing assistance to a new set of COVID-19 testing technologies as component of its initiative to boost diagnostics in the region.

Pathology Laboratories Market Report Highlights:

Based on type, hospital-based diagnostic labs dominated the market during the year 2024. This can be attributed to the advanced tests available at hospitals, making them the only best solution for complex diagnosis
Based on the end use, physician referrals dominated the market in 2024. Walk-in and corporate clients are expected to witness lucrative growth due to increased self-awareness for monitoring health and wellness among individuals
U.S. is expected to have a high demand for the diagnosis of cardiovascular health as a result of the most prominent disease in the U.S.
Europe is expected to have a significant CAGR during the forecast period. Denmark has the highest prevalence of cancer globally in terms of cancer prevalence as per the World Cancer Research Fund International
The market is witnessing multiple collaborations in recent times with the key players aiming at adding value to their services & expanding their research. For Instance, in July 2022, Unilabs announced a partnership with Subtle Medical, to be the first diagnostic company to adopt their AI-based MRI technology for high-quality & quick MRI. The solution will be first launched in Sweden.

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Segment Definitions
- 1.2.1. Type
- 1.2.2. Testing Services
- 1.2.3. End Use
- 1.2.4. Regional Scope
- 1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Regional outlook
2.4. Competitive Insights

Chapter 3. Pathology Laboratories Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
  - 3.2.1.1. Improving healthcare infrastructure in developing countries
  - 3.2.1.2. Increasing demand for regular general health check-ups
  - 3.2.1.3. Gowning reimbursement for diagnostics services
- 3.2.2. Market Restraint Analysis
  - 3.2.2.1. Affordability for high-end molecular diagnostics
  - 3.2.2.2. Shortage of skilled workforce
3.3. Pathology Laboratories Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Bargaining power of suppliers
  - 3.3.1.2. Bargaining power of buyers
  - 3.3.1.3. Threat of substitutes
  - 3.3.1.4. Threat of new entrants
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Economic landscape
  - 3.3.2.3. Social landscape
  - 3.3.2.4. Technological landscape
  - 3.3.2.5. Environmental landscape
  - 3.3.2.6. Legal landscape

Chapter 4. Pathology Laboratories Market: Type Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Pathology Laboratories Market: Type Movement Analysis
4.3. Pathology Laboratories Market by Type Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Hospital Based
- 4.5.1. Hospital Based Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Standalone Labs
- 4.6.1. Standalone Labs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Diagnostic Chains
- 4.7.1. Diagnostic Chains Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Pathology Laboratories Market: Testing Services Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Pathology Laboratories Market: Testing Services Movement Analysis
5.3. Pathology Laboratories Market by Testing Services Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. General Physiological & Clinical Tests
- 5.5.1. General Physiological & Clinical Tests Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Imaging & Radiology Tests
- 5.6.1. Imaging & Radiology Tests Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Esoteric Tests
- 5.7.1. Esoteric Tests Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. COVID-19 Tests
- 5.8.1. COVID-19 Tests Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Pathology Laboratories Market: End Use Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Pathology Laboratories Market: End Use Movement Analysis
6.3. Pathology Laboratories Market by End Use Outlook (USD Million)
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5. Physician Referrals
- 6.5.1. Physician Referrals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Walk-Ins
- 6.6.1. Walk-Ins Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Corporate
- 6.7.1. Corporate Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Pathology Laboratories Market: Regional Estimates & Trend Analysis

7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
- 7.3.1. U.S.
  - 7.3.1.1. Key country dynamics
  - 7.3.1.2. Regulatory framework/ reimbursement structure
  - 7.3.1.3. Competitive scenario
  - 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 7.3.2. Canada
  - 7.3.2.1. Key country dynamics
  - 7.3.2.2. Regulatory framework/ reimbursement structure
  - 7.3.2.3. Competitive scenario
  - 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 7.3.3. Mexico
  - 7.3.3.1. Key country dynamics
  - 7.3.3.2. Regulatory framework/ reimbursement structure
  - 7.3.3.3. Competitive scenario
  - 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
- 7.4.1. UK
  - 7.4.1.1. Key country dynamics
  - 7.4.1.2. Regulatory framework/ reimbursement structure
  - 7.4.1.3. Competitive scenario
  - 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.2. Germany
  - 7.4.2.1. Key country dynamics
  - 7.4.2.2. Regulatory framework/ reimbursement structure
  - 7.4.2.3. Competitive scenario
  - 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.3. France
  - 7.4.3.1. Key country dynamics
  - 7.4.3.2. Regulatory framework/ reimbursement structure
  - 7.4.3.3. Competitive scenario
  - 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.4. Italy
  - 7.4.4.1. Key country dynamics
  - 7.4.4.2. Regulatory framework/ reimbursement structure
  - 7.4.4.3. Competitive scenario
  - 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.5. Spain
  - 7.4.5.1. Key country dynamics
  - 7.4.5.2. Regulatory framework/ reimbursement structure
  - 7.4.5.3. Competitive scenario
  - 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.6. Norway
  - 7.4.6.1. Key country dynamics
  - 7.4.6.2. Regulatory framework/ reimbursement structure
  - 7.4.6.3. Competitive scenario
  - 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.7. Sweden
  - 7.4.7.1. Key country dynamics
  - 7.4.7.2. Regulatory framework/ reimbursement structure
  - 7.4.7.3. Competitive scenario
  - 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 7.4.8. Denmark
  - 7.4.8.1. Key country dynamics
  - 7.4.8.2. Regulatory framework/ reimbursement structure
  - 7.4.8.3. Competitive scenario
  - 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
- 7.5.1. Japan
  - 7.5.1.1. Key country dynamics
  - 7.5.1.2. Regulatory framework/ reimbursement structure
  - 7.5.1.3. Competitive scenario
  - 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.2. China
  - 7.5.2.1. Key country dynamics
  - 7.5.2.2. Regulatory framework/ reimbursement structure
  - 7.5.2.3. Competitive scenario
  - 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.3. India
  - 7.5.3.1. Key country dynamics
  - 7.5.3.2. Regulatory framework/ reimbursement structure
  - 7.5.3.3. Competitive scenario
  - 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.4. Australia
  - 7.5.4.1. Key country dynamics
  - 7.5.4.2. Regulatory framework/ reimbursement structure
  - 7.5.4.3. Competitive scenario
  - 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.5. South Korea
  - 7.5.5.1. Key country dynamics
  - 7.5.5.2. Regulatory framework/ reimbursement structure
  - 7.5.5.3. Competitive scenario
  - 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 7.5.6. Thailand
  - 7.5.6.1. Key country dynamics
  - 7.5.6.2. Regulatory framework/ reimbursement structure
  - 7.5.6.3. Competitive scenario
  - 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
- 7.6.1. Brazil
  - 7.6.1.1. Key country dynamics
  - 7.6.1.2. Regulatory framework/ reimbursement structure
  - 7.6.1.3. Competitive scenario
  - 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 7.6.2. Argentina
  - 7.6.2.1. Key country dynamics
  - 7.6.2.2. Regulatory framework/ reimbursement structure
  - 7.6.2.3. Competitive scenario
  - 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
- 7.7.1. South Africa
  - 7.7.1.1. Key country dynamics
  - 7.7.1.2. Regulatory framework/ reimbursement structure
  - 7.7.1.3. Competitive scenario
  - 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.2. Saudi Arabia
  - 7.7.2.1. Key country dynamics
  - 7.7.2.2. Regulatory framework/ reimbursement structure
  - 7.7.2.3. Competitive scenario
  - 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.3. UAE
  - 7.7.3.1. Key country dynamics
  - 7.7.3.2. Regulatory framework/ reimbursement structure
  - 7.7.3.3. Competitive scenario
  - 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 7.7.4. Kuwait
  - 7.7.4.1. Key country dynamics
  - 7.7.4.2. Regulatory framework/ reimbursement structure
  - 7.7.4.3. Competitive scenario
  - 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Market Participant Categorization
8.2. Recent Developments & Impact Analysis by Key Market Participants
8.3. Company Market Share Analysis, 2024
8.4. Key Company Profiles
- 8.4.1. Quest Diagnostics Incorporated
  - 8.4.1.1. Company overview
  - 8.4.1.2. Financial performance
  - 8.4.1.3. Product benchmarking
  - 8.4.1.4. Strategic initiatives
- 8.4.2. Eurofins Scientific
  - 8.4.2.1. Company overview
  - 8.4.2.2. Financial performance
  - 8.4.2.3. Product benchmarking
  - 8.4.2.4. Strategic initiatives
- 8.4.3. Laboratory Corporation of America Holdings
  - 8.4.3.1. Company overview
  - 8.4.3.2. Financial performance
  - 8.4.3.3. Product benchmarking
  - 8.4.3.4. Strategic initiatives
- 8.4.4. Exact Sciences Laboratories LLC
  - 8.4.4.1. Company overview
  - 8.4.4.2. Financial performance
  - 8.4.4.3. Product benchmarking
  - 8.4.4.4. Strategic initiatives
- 8.4.5. Spectra Laboratories
  - 8.4.5.1. Company overview
  - 8.4.5.2. Financial performance
  - 8.4.5.3. Product benchmarking
  - 8.4.5.4. Strategic initiatives
- 8.4.6. SYNLAB International GmbH
  - 8.4.6.1. Company overview
  - 8.4.6.2. Financial performance
  - 8.4.6.3. Product benchmarking
  - 8.4.6.4. Strategic initiatives
- 8.4.7. Sonic Healthcare Limited
  - 8.4.7.1. Company overview
  - 8.4.7.2. Financial performance
  - 8.4.7.3. Product benchmarking
  - 8.4.7.4. Strategic initiatives
- 8.4.8. DR Lal Path Labs.
  - 8.4.8.1. Company overview
  - 8.4.8.2. Financial performance
  - 8.4.8.3. Product benchmarking
  - 8.4.8.4. Strategic initiatives
- 8.4.9. Metropolis Healthcare
  - 8.4.9.1. Company overview
  - 8.4.9.2. Financial performance
  - 8.4.9.3. Product benchmarking
  - 8.4.9.4. Strategic initiatives
- 8.4.10. Kingmed Diagnostics
  - 8.4.10.1. Company overview
  - 8.4.10.2. Financial performance
  - 8.4.10.3. Product benchmarking
  - 8.4.10.4. Strategic initiatives